BDNF and NT-3 applied in the whisker pad reverse cortical changes after peripheral deafferentation in neonatal rats.
It has been known for a long time that subcortical input drives the specification of cortical areas. Molecular signals mediating this instructive effect from the periphery are poorly understood. In foetal or neonatal rats, ablation of whisker follicles, transection of the infraorbital nerve, inhibition of axonal transport, but not impulse activity blockade, prevent formation of barrels in the primary somatosensory cortex (S1). These findings suggest that a chemical signal, possibly arising from the skin or the follicle, may be responsible for somatotopic pattern formation in S1. Neurotrophins promote survival and differentiation of primary sensory neurons, and are expressed in the whisker pad during development. Neonatal rats received gelfoam impregnated with NGF, BDNF or NT-3 under the whisker pad following surgical denervation of whisker rows D and E on P0. Barrel formation in S1 was assessed on P7 by acetylcholinesterase histochemistry and 5-HT-immunohistochemistry. BDNF and NT-3, but not NGF, promoted development of the cortical barrels corresponding to denervated whiskers. Furthermore, BDNF and NT-3 prevented the lesion-induced expansion of row C barrels, while NGF appeared to promote row C expansion. Our results suggest that BDNF and NT-3 arising from the whisker pad are involved in the formation and/or maintenance of the barrel pattern in S1. These findings are potentially relevant for the prevention of sensory disturbances possibly due to reorganization of central sensory circuits after peripheral nerve lesions in humans.
Calia
E
E
Department of Physiology, Università Campus Bio-Medico, Rome, Italy.
Persico
A M
AM
Baldi
A
A
Keller
F
F
D000110:Acetylcholinesterase / Q000032:analysis; D000818:Animals; D000831:Animals, Newborn; D015415:Biomarkers; D019208:Brain-Derived Neurotrophic Factor / Q000008:administration & dosage / Q000494:pharmacology*; D002675:Child, Preschool; D003714:Denervation; D004333:Drug Administration Routes; D004343:Drug Implants; D006651:Histocytochemistry; D006801:Humans; D007150:Immunohistochemistry; D009414:Nerve Growth Factors / Q000008:administration & dosage / Q000494:pharmacology*; D009475:Neurons, Afferent / Q000187:drug effects*; D020933:Neurotrophin 3; D010525:Peripheral Nerves / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D011917:Rats, Inbred Lew; D012701:Serotonin / Q000032:analysis; D013003:Somatosensory Cortex / Q000187:drug effects* / Q000473:pathology; D014738:Vibrissae / Q000294:innervation
D015415:Biomarkers; D019208:Brain-Derived Neurotrophic Factor; D004343:Drug Implants; D009414:Nerve Growth Factors; D020933:Neurotrophin 3; D012701:Serotonin; D000110:Acetylcholinesterase